Lamivudine/nevirapine/stavudine - Emcure Pharmaceuticals

Drug Profile

Lamivudine/nevirapine/stavudine - Emcure Pharmaceuticals

Alternative Names: Lamivudine/stavudine/nevirapine - Emcure Pharmaceuticals; Nevirapine/lamivudine/stavudine - Emcure Pharmaceuticals; Nevirapine/stavudine/lamivudine - Emcure Pharmaceuticals; Stavudine/lamivudine/nevirapine - Emcure Pharmaceuticals; Stavudine/nevirapine/lamivudine - Emcure Pharmaceuticals

Latest Information Update: 06 Aug 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Emcure Pharmaceuticals
  • Class Antiretrovirals; Dideoxynucleosides; Nucleosides; Pyrimidine nucleosides
  • Mechanism of Action Non-nucleoside reverse transcriptase inhibitors; Nucleoside reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration HIV-1 infections

Most Recent Events

No Data Available
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top